AI Science Tracker
EN

Learned breast-cancer feature selection nominates survival-associated transcripts

International Centre for Genetic Engineering and Biotechnology; Regional Centre for Biotechnology · 24 Mar 2022 · medicine

Discovery

Learned breast-cancer feature selection nominates survival-associated transcripts

Source check: Source checked. Not independent scientific confirmation.

Finding: Random-forest recursive feature elimination and XGBoost analysis of breast-cancer expression data nominated genes subsequently associated with distant-metastasis-free survival in a basal breast-cancer subgroup. Higher POU2AF1 and S100B expression was associated with longer survival in the reported analysis. These are exploratory expression–outcome associations, not causal mechanisms or a clinically validated prognostic test.

Technology: Random-forest recursive feature elimination; XGBoost

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
Fitted random-forest feature elimination and boosted-tree classification narrow the candidate transcript sets before the scoped posthoc clinical-outcome association analysis.
Test and result
The source pooled 1,150 expression samples, including 623 triple-negative cases, to learn subtype-discriminating gene sets. Genes passing further differential-expression filtering were examined with KM Plotter and Cox analysis for distant-metastasis-free survival.
Limitation / still unknown
External subtype classification helped choose the final gene sets and is not an untouched evaluation of survival prognosis. Survival analysis used a St Gallen basal-subtype definition; exact survival sample counts, cutoff selection, overlap with discovery samples and multiplicity control are not fully resolved in the inspected main text. Whole-data batch adjustment and unclear feature-selection nesting can inflate classification performance, so those metrics are not the represented finding. CT83 p=.052 is not treated as significant. No perturbation or clinical-treatment effect is established.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC9014315/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 21 Nov 2026. Review scope: Exact primary front and scoped computational/clinical model Methods and corresponding Results; no operational laboratory protocols evaluated.

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open in the full catalog for filters, charts and related discoveries. Browse medicine discoveries.